Integral Diagnostics Valuation

Q: What is the Fair Price of ITGD.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ITGD.F ($2.1) is trading below our estimate of [[fair value]] ($5.67)

Is ITGD.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ITGD.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ITGD.F ($2.1) is trading below our estimate of fair value ($5.67)

Significantly Below Fair Value: ITGD.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ITGD.F?

Key metric: As ITGD.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ITGD.F. This is calculated by dividing ITGD.F's market cap by their current revenue.
What is ITGD.F's PS Ratio?
PS Ratio	1.3x
Sales	AU$456.31m
Market Cap	AU$570.75m

ITGD.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2x
Enterprise Value/EBITDA	12.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ITGD.F's PS Ratio compare to its peers?

The above table shows the PS ratio for ITGD.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.1x
AIRS AirSculpt Technologies	2.1x	9.2%	US$395.3m
ACCD Accolade	0.7x	11.4%	US$310.9m
VMD Viemed Healthcare	1.6x	12.9%	US$337.6m
MODV ModivCare	0.09x	5.7%	US$268.4m
ITGD.F Integral Diagnostics	1.3x	5.9%	US$570.8m

Price-To-Sales vs Peers: ITGD.F is expensive based on its Price-To-Sales Ratio (1.3x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does ITGD.F's PS Ratio compare vs other companies in the US Healthcare Industry?

29 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$79.78b
CVS CVS Health	0.2x	4.5%	US$75.32b
COR Cencora	0.2x	6.5%	US$48.62b
CNC Centene	0.2x	5.5%	US$30.29b

29 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ITGD.F is expensive based on its Price-To-Sales Ratio (1.3x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is ITGD.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ITGD.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ITGD.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.